person · Reporting owner
Thepaut Eric Francis Yves
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Pres, Eur, Mid-East, Afr | May 10, 2024 | May 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date May 10, 2024 · Filed May 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,421.99 |
Ending reported balance
After 2024-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-10 · Exercise / conversion · Acquired 12,931 · Balance 44,352.99 Row 2 · 2024-05-10 · Sale · Disposed 12,931 · Balance 31,421.99 F1: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.13 to $74.165, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.31 · Expires 2025-02-23 | Direct | 0 |
Reported balance
After 2024-05-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-10 · Exercise / conversion · Disposed 12,931 · Balance 0 F2: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.13 to $74.165, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 11,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000445 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,578 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,548 | $35.34 | $90,046.32 |
DisclosureSEC source: 0001225208-19-000445 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,728.99 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 11,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000445 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,276.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328 Underlying: Common Stock · 2,327 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 512 | $37.67 | $19,287.04 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,698.99 Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 21:56 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-016169 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,210.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,298 | $36.74 | $562,019.45 |
DisclosureSEC source: 0001225208-18-016089 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,883.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.73 to $36.78, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,458 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 24, 2010, the first anniversary of the date of grant. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 23,458 | $37.51 | $879,886.12 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,181.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.545, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 23,458 | $8.30 | $194,701.40 |
DisclosureSEC source: 0001225208-18-015461 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,639.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,697 shares Expires 2018-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 374 | $35.38 | $13,232.12 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,181.99 Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-014957 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,555.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20,015 | $30.15 | $603,368.19 |
DisclosureSEC source: 0001225208-18-009556 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,858.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.14 to $30.155, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004951 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,413 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004951 · doc4.xml · derivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,332 Underlying: Common Stock · 1,832 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,595 | $27.26 | $43,479.70 |
DisclosureSEC source: 0001225208-18-004951 · doc4.xml · nonDerivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,873.99 Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004951 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,468.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004951 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,636.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · derivative · entry 6 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Stock · 1,529 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 337 | $27.20 | $9,166.40 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · nonDerivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,223.99 Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · nonDerivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,560.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840 Underlying: Common Stock · 920 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 203 | $27.20 | $5,521.60 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,031.99 Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 22:44 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004208 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,234.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004014 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,084 Underlying: Common Stock · 2,028 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 447 | $26.48 | $11,836.56 |
DisclosureSEC source: 0001225208-18-004014 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,314.99 Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004014 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,761.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 27,808 | $0.00 Strike: $27.09 | $0.00 |
DisclosureSEC source: 0001225208-18-003403 · doc4.xml · derivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,808 Underlying: Common Stock · 27,808 shares Expires 2028-02-15 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:57 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 9,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003403 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,228 Underlying: Common Stock · 9,228 shares Expires 2023-02-15 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 8,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002916 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 Underlying: Common Stock · 8,944 shares Expires 2019-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. F3 · balance_after: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2019. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,024 | $26.18 | $52,988.32 |
DisclosureSEC source: 0001225208-18-002916 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,733.99 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:50 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 9,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002916 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,757.99 F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2017 and was subject to the completion of the concurrent three-year individual service period. On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 5,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000433 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,003 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.exercise_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. F1 · derivative.expiration_date: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,101 | $24.79 | $27,293.79 |
DisclosureSEC source: 0001225208-18-000433 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,561.99 Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 23:06 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-000433 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,662.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 23, 2015, the reporting person was awarded a target number of performance share units under the Company's 2015 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2015 adjusted free cash flow measured against its 2015 financial plan over the one-year performance period ending December 31, 2015 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2016, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2017. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,655 Underlying: Common Stock · 2,327 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 512 | $26.15 | $13,388.80 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,659.99 Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 22:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018119 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,171.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,697 Underlying: Common Stock · 1,696 shares Expires 2018-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant. Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 374 | $28.50 | $10,659.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,844.99 Read SEC document |
| October 29, 2017 Filed Oct 31, 2017 20:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-016690 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,218.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 29,644 | $0.00 Strike: $24.55 | $0.00 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · derivative · entry 6 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,644 Underlying: Common Stock · 29,644 shares Expires 2027-02-28 F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 11,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,578 Underlying: Common Stock · 11,578 shares Expires 2018-12-31 F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F5 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F5 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. F5 · balance_after: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · derivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,413 Underlying: Common Stock · 5,413 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 9,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,164 Underlying: Common Stock · 9,164 shares Expires 2022-02-28 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,191 | $24.55 | $29,239.05 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,522.99 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005440 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,713.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004955 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,300 shares Expires 2017-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 22:59 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 946 | $24.81 | $23,470.26 |
DisclosureSEC source: 0001225208-17-004955 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,300.99 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.